Research programme: calcium channel stabilisers - ARMGO Pharma

Drug Profile

Research programme: calcium channel stabilisers - ARMGO Pharma

Alternative Names: Ryanodine receptor calcium-release channel (RyR) modulators - ARMGO Pharma; Rycals; S 107

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARMGO Pharma
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cognition disorders; Musculoskeletal disorders
  • Research Alzheimer's disease; Diabetes mellitus; Huntington's disease; Post-traumatic stress disorders

Most Recent Events

  • 17 Aug 2017 Early research in Alzheimer's disease in USA (PO) prior to August 2017 (ARMGO Pharma pipeline, August 2017)
  • 17 Aug 2017 Early research in Diabetes mellitus in USA (PO) prior to August 2017 (ARMGO Pharma pipeline, August 2017)
  • 17 Aug 2017 Early research in Huntington's disease in USA (PO) prior to August 2017 (ARMGO Pharma pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top